Samsara BioCapital’s Inozyme Pharma INZY Stock Holding History

Samsara BioCapital’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,562,500	Closed	-$1.42M	–	33
2025 Q1	$1.42M	Hold	1,562,500	–	–	0.25%	24
2024 Q4	$4.33M	Hold	1,562,500	–	–	0.59%	25
2024 Q3	$8.17M	Hold	1,562,500	–	–	1.57%	17
2024 Q2	$6.97M	Hold	1,562,500	–	–	1.46%	18
2024 Q1	$12M	Hold	1,562,500	–	–	1.85%	15
2023 Q4	$6.66M	Hold	1,562,500	–	–	1.04%	20
2023 Q3	$6.56M	Buy	+1,562,500	New	+$7.95M	2.01%	14
2023 Q2	–	Sell	-504,407	Closed	-$2.89M	–	51
2023 Q1	$2.89M	Buy	+504,407	New	+$1.33M	0.6%	27

Other funds holding INZY

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Samsara BioCapital's INZY Position: Q2 2025 in Review

Samsara BioCapital sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 1,562,500 shares — an estimated $1.42M sold.

Samsara BioCapital first reported a position in INZY in Q1 2023 and held it in 8 quarters. The position peaked at $12M in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

Samsara BioCapital reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
Samsara BioCapital sold 1,562,500 Inozyme Pharma shares in Q2 2025, an estimated $1.42M.
Samsara BioCapital first reported a position in Inozyme Pharma in Q1 2023 and held it in 8 quarters.
Samsara BioCapital's Inozyme Pharma position peaked at $12M in Q1 2024.
86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Samsara BioCapital's 13F filing for Q2 2025, filed 14 Aug 2025.